The Genetic Core will assess the genetic contribution to familial Parkinson's disease and atypical parkinsonism. It will aid in molecular diagnosis for the Cinical and Neuropathology Cores and will serve Projects by Farrer and Dickson. Genes implicated in a phenotype of parkinsonism are to be sequenced and quantitatively assessed using Taqman/ABI3100 and fluorescent in-situ hybridization. Analysis will include all exons of the PRKN and DJ-1 genes in early-onset parkinsonism (<50 years at onset), as well as genes indirectly implicated either biochemically within a common pathway or through linkage/association analyses. The frequency of any variant found will be assessed in a large number of appropriate population controls. Genes/mutations will be cloned and made publically accessible to other researchers. Power analysis will prioritize family collections for the Clinical Core and guide pedigree expansion. Known loci will be examined through limited marker genotyping in regions implicated in previous genome searches, but for which the gene has yet to be identified (PARK3, 6, 8-11). The genetic contribution to disease in large multi-incident families, excluded from known loci, will subsequently be explored by genome-wide genotyping and model-based linkage and haplotype analyses. For smaller sets of families (2+ affecteds) or without a clearly demonstrable mode of inheritance, non-parametric allele sharing methods may be employed. Support will go into genetic analysis software, a package of perl scripts/open source statistical algorithms running on Linux OS, for wider distribution to other groups.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZNS1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic Jacksonville
United States
Zip Code
Verma, Manish; Callio, Jason; Otero, P Anthony et al. (2017) Mitochondrial Calcium Dysregulation Contributes to Dendrite Degeneration Mediated by PD/LBD-Associated LRRK2 Mutants. J Neurosci 37:11151-11165
Sanchez-Contreras, Monica; Heckman, Michael G; Tacik, Pawel et al. (2017) Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration. Mov Disord 32:115-123
Hassan, Anhar; Heckman, Michael G; Ahlskog, J E et al. (2016) Association of Parkinson disease age of onset with DRD2, DRD3 and GRIN2B polymorphisms. Parkinsonism Relat Disord 22:102-5
Yue, M; Hinkle, K M; Davies, P et al. (2015) Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol Dis 78:172-95
Cornejo-Olivas, Mario R; Torres, Luis; Mata, Ignacio F et al. (2015) A Peruvian family with a novel PARK2 mutation: Clinical and pathological characteristics. Parkinsonism Relat Disord 21:444-8
Verma, Manish; Steer, Erin K; Chu, Charleen T (2014) ERKed by LRRK2: a cell biological perspective on hereditary and sporadic Parkinson's disease. Biochim Biophys Acta 1842:1273-81
Foroutan, Parastou; Murray, Melissa E; Fujioka, Shinsuke et al. (2013) Progressive supranuclear palsy: high-field-strength MR microscopy in the human substantia nigra and globus pallidus. Radiology 266:280-8
Jiang, Peizhou; Gan, Ming; Ebrahim, Abdul Shukkur et al. (2013) Adenosine monophosphate-activated protein kinase overactivation leads to accumulation of ýý-synuclein oligomers and decrease of neurites. Neurobiol Aging 34:1504-15
Whitwell, Jennifer L; Xu, Jia; Mandrekar, Jay et al. (2013) Frontal asymmetry in behavioral variant frontotemporal dementia: clinicoimaging and pathogenetic correlates. Neurobiol Aging 34:636-9
Sundal, Christina; Fujioka, Shinsuke; Van Gerpen, Jay A et al. (2013) Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations. Parkinsonism Relat Disord 19:869-77

Showing the most recent 10 out of 205 publications